Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells

Oridonin (ORI) is known to pose anticancer activity against cancer, which could induce the therapeutic impact of chemotherapy drugs. However, such simple combinations have numerous side effects such as higher toxicity to normal cells and tissues. To enhance the therapeutic effects with minimal side...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Huiyu, Wang, Jie, Khan, Suliman, Zhang, Yuanying, Zhu, Kuicheng, Zhou, Enhui, Gong, Meiyuan, Liu, Bingrong, Kan, Quancheng, Zhang, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Pre-Clinical Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670348/
https://www.ncbi.nlm.nih.gov/pubmed/34520434
http://dx.doi.org/10.1097/CAD.0000000000001237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670348/
https://www.ncbi.nlm.nih.gov/pubmed/34520434
http://dx.doi.org/10.1097/CAD.0000000000001237

Ejemplares similares